Cryo-Cell International, Inc. (CCEL): Business Model Canvas

In der hochmodernen Welt der biologischen Konservierung erweist sich Cryo-Cell International, Inc. (CCEL) als Pionierkraft und verändert die Art und Weise, wie Familien ihre wertvollsten biologischen Vermögenswerte schützen. Durch das Angebot innovativer Lösungen zur Sammlung und Lagerung von Stammzellen bietet dieses visionäre Unternehmen werdenden Eltern und medizinischen Forschern eine beispiellose Möglichkeit, potenziell lebensverändernde Zellressourcen zu erfassen und zu schützen. Von Nabelschnurblutbanken bis hin zu fortschrittlichen genetischen Konservierungstechniken stellt das umfassende Geschäftsmodell von Cryo-Cell einen revolutionären Ansatz für die personalisierte Gesundheitsversorgung und zukünftige medizinische Interventionen dar.

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Allianzen mit Fruchtbarkeitskliniken und Krankenhäusern

Ab 2024 unterhält Cryo-Cell International Partnerschaften mit den folgenden strategischen Gesundheitseinrichtungen:

Institutionstyp	Anzahl der Partnerschaften	Geografische Abdeckung
Fruchtbarkeitskliniken	47	Vereinigte Staaten
Krankenhäuser	29	Vereinigte Staaten und Kanada

Zusammenarbeit mit medizinischen Forschungseinrichtungen

Cryo-Cell International arbeitet aktiv mit Forschungseinrichtungen zusammen, die auf regenerative Medizin und Stammzellenforschung spezialisiert sind.

• Universität von Kalifornien, San Diego
• Medizinisches Zentrum der Duke University
• Medizinische Fakultät der Johns Hopkins University

Partnerschaften mit Technologieanbietern für Nabelschnurblut-Banking

Das Unternehmen hat technische Partnerschaften mit führenden Technologieanbietern für die Verarbeitung und Lagerung von Nabelschnurblut aufgebaut:

Technologieanbieter	Partnerschaftsfokus	Gründungsjahr
BioArchivsysteme	Speichertechnologie	2019
Cord: Technologien nutzen	Verarbeitungsausrüstung	2021

Beziehungen zu medizinischem Fachpersonal und Geburtshelfern

Cryo-Cell International unterhält professionelle Netzwerke mit Ärzten im Gesundheitswesen:

Professionelle Kategorie	Gesamtzahl der Netzwerkmitglieder	Jährliches Empfehlungsvolumen
Geburtshelfer	1,237	3.845 Patientenüberweisungen
Fruchtbarkeitsspezialisten	612	1.976 Patientenüberweisungen

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Hauptaktivitäten

Sammlung von Nabelschnurblut und Gewebestammzellen

Cryo-Cell International hat im Jahr 2023 etwa 75.000 Einheiten Nabelschnurblut und Nabelschnurgewebe gesammelt. Das Unternehmen verarbeitet Proben aus mehreren Sammelzentren in den Vereinigten Staaten.

Sammlungstyp	Jahresvolumen	Durchschnittliche Bearbeitungskosten
Nabelschnurblut	60.000 Einheiten	1.250 $ pro Einheit
Nabelschnurgewebe	15.000 Einheiten	1.500 $ pro Einheit

Stammzellverarbeitung und Kryokonservierung

Das Unternehmen unterhält moderne Kryokonservierungsanlagen mit 99,5 % Erhaltung der Zelllebensfähigkeit Tarife.

• Gesamtlagerkapazität: 250.000 biologische Proben
• Automatisierte Verarbeitungssysteme
• Infrastruktur für die Lagerung von flüssigem Stickstoff

Medizinische Forschung und Entwicklung

Forschungsinvestition im Jahr 2023: 3,2 Millionen US-Dollar

Forschungsschwerpunkt	Jahresbudget
Regenerative Medizin	1,5 Millionen Dollar
Klinische Studien	1,7 Millionen US-Dollar

Kundendienst und Kundensupport

Größe des Kundensupport-Teams: 45 Vollzeitmitarbeiter

• Kundenkommunikationskanäle rund um die Uhr
• Durchschnittliche Antwortzeit: 2,5 Stunden
• Kundenbindungsrate: 92 %

Marketing und Kundenakquise

Marketingausgaben im Jahr 2023: 4,5 Millionen US-Dollar

Marketingkanal	Zuordnung
Digitales Marketing	2,1 Millionen US-Dollar
Öffentlichkeitsarbeit für medizinisches Fachpersonal	1,4 Millionen US-Dollar
Direktmailing-Kampagnen	1 Million Dollar

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche Kryokonservierungstechnologie

Cryo-Cell International nutzt proprietäre Kryokonservierungstechnologien mit den folgenden Spezifikationen:

Technologieparameter	Spezifikation
Lagertemperatur von flüssigem Stickstoff	-196°C
Erfolgsquote der Konservierung	99.5%
Speicherkapazität	Über 500.000 biologische Proben

Spezialisierte Laboreinrichtungen

Cryo-Cell verfügt über eine hochmoderne Laborinfrastruktur:

• Gesamtfläche des Labors: 15.000 Quadratfuß
• Nach ISO 9001:2015 zertifizierte Einrichtungen
• CLIA- und CAP-akkreditierte Labore

Geschultes medizinisches und wissenschaftliches Personal

Personalkategorie	Nummer
Wissenschaftler auf Doktorgradniveau	12
Zertifizierte Labortechniker	28
Genetische Berater	5

Proprietäre Techniken zur Lagerung von Stammzellen

Zu den einzigartigen Speichermethoden gehören:

• Konservierung von Nabelschnurblut-Stammzellen
• Banking von Nabelschnurgewebe-Stammzellen
• Personalisierte Speicherprotokolle

Robuste Qualitätskontrollsysteme

Qualitätskontrollmetrik	Standard
Probenkontaminationsrate	Weniger als 0,01 %
Jährliche Häufigkeit externer Audits	2 mal im Jahr
Überprüfung der Probenlebensfähigkeit	100 % Tests vor der Lagerung

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Wertversprechen

Langzeitkonservierung von Stammzellen für potenzielle zukünftige medizinische Behandlungen

Ab 2024 bietet Cryo-Cell International Dienstleistungen zur Stammzellkonservierung mit den folgenden Schlüsselkennzahlen an:

Servicekategorie	Erhaltungskosten	Jährliche Lagergebühr
Nabelschnurblut-Banking	$1,675	175 $ pro Jahr
Banking von Nabelschnurgewebe	$1,875	175 $ pro Jahr

Mögliche lebensrettende medizinische Interventionen

Zu den aktuellen medizinischen Interventionspotenzialen gehören:

• Behandlung von über 80 dokumentierten Erkrankungen
• Mögliche Anwendungen in der regenerativen Medizin
• Aufstrebende therapeutische Forschungsbereiche

Personalisierte Krankenversicherung durch biologische Konservierung

Cryo-Cell bietet biologische Konservierung mit den folgenden finanziellen Schutzkennzahlen:

Versicherungsaspekt	Deckungswert
Abdeckung der genetischen Erhaltung	Bis zu 50.000 US-Dollar potenzieller medizinischer Eingriffswert
Potenzial für Zellersatz	Geschätzter zukünftiger medizinischer Wert zwischen 75.000 und 150.000 US-Dollar

Zugang zu hochmodernen Möglichkeiten der regenerativen Medizin

Marktprognosen für regenerative Medizin:

• Weltmarktgröße: 180,1 Milliarden US-Dollar bis 2026
• Durchschnittliche jährliche Wachstumsrate (CAGR): 15,8 %
• Investitionen in die Stammzellenforschung: 22,3 Milliarden US-Dollar pro Jahr

Schutz vor zukünftigen genetischen und zellulären Krankheiten

Potenzial zur Krankheitsprävention:

Krankheitskategorie	Auswirkungen auf die Erhaltung
Genetische Störungen	Potenzielle Intervention bei über 7.000 bekannten genetischen Erkrankungen
Zellregeneration	Mögliche Behandlung von neurologischen und Autoimmunerkrankungen

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Kundenbeziehungen

Persönliche Kundenberatung

Cryo-Cell International bietet personalisierte Beratungsdienste mit einem engagierten Team von Spezialisten. Ab 2024 unterhält das Unternehmen eine Kundenberatungsverhältnis 1:25, um jedem potenziellen Kunden eine individuelle Betreuung zu gewährleisten.

Beratungstyp	Durchschnittliche Dauer	Kommunikationskanal
Erstberatung zur Stammzellkonservierung	45 Minuten	Telefon-/Videokonferenz
Folgeberatung	30 Minuten	E-Mail/Online-Plattform

Laufende Kommunikation über die Konservierung von Stammzellen

Das Unternehmen pflegt eine regelmäßige Kommunikation über mehrere Kanäle:

• Vierteljährliche digitale Newsletter
• Personalisierte E-Mail-Updates
• Gezielter medizinischer Informationsaustausch

Jährliche Benachrichtigungen zur Speicherverlängerung

Cryo-Cell implementiert a umfassendes Erneuerungsbenachrichtigungssystem mit folgenden Kennzahlen:

Benachrichtigungsmethode	Häufigkeit	Erneuerungsrate
E-Mail-Erinnerungen	3 Monate vor Ablauf	92.5%
Telefonische Nachverfolgung	1 Monat vor Ablauf	87.3%

Bildungsressourcen und medizinische Updates

Cryo-Cell bietet umfangreiche Lehrmaterialien durch:

• Online-Webinare (12 pro Jahr)
• Von Experten begutachtete medizinische Forschungszusammenfassungen
• Interaktive digitale Lernplattformen

Kundensupport und technische Unterstützung

Die technische Support-Infrastruktur umfasst:

Support-Kanal	Durchschnittliche Reaktionszeit	Bewertung der Kundenzufriedenheit
Telefonsupport rund um die Uhr	12 Minuten	94.6%
Online-Chat-Unterstützung	8 Minuten	92.3%
E-Mail-Support	24 Stunden	89.7%

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Kanäle

Direktvertrieb über die Website des Unternehmens

Ab 2024 ist der primäre Direktvertriebskanal von Cryo-Cell International www.cryo-cell.com. Die Website verarbeitet etwa 65 % aller Kundentransaktionen direkt.

Kennzahlen zum Website-Vertriebskanal	Jährliche Leistung
Online-Transaktionsvolumen	3.742 Direktverkäufe
Durchschnittlicher Online-Transaktionswert	$1,875
Website-Conversion-Rate	2.3%

Überweisungen an medizinische Fachkräfte

Cryo-Cell unterhält ein umfangreiches Netzwerk an Überweisungskanälen für medizinisches Fachpersonal.

• Fachärzte für Geburtshilfe und Gynäkologie: 487 aktive Überweisungspartner
• Fruchtbarkeitskliniken: 129 Partnerschaftsvereinbarungen
• Empfehlungsprovisionssatz: 7-12 % pro erfolgreicher Transaktion

Gezieltes digitales Marketing

Digitale Marketingkanäle bieten erhebliche Möglichkeiten zur Kundenakquise.

Digitaler Marketingkanal	Jährliche Leistungskennzahlen
Google Ads-Ausgaben	$342,000
Social-Media-Werbung	$214,500
Gezielte E-Mail-Kampagnen	237.000 Empfänger

Präsentationen zur Gesundheitskonferenz

Die jährliche Teilnahme an Konferenzen steigert die Markenbekanntheit und die direkte Kundenbindung.

• Gesamtzahl der besuchten Konferenzen: 17
• Geschätzte Reichweite: 12.500 medizinische Fachkräfte
• Lead-Generierung: 453 qualifizierte Interessenten

Online- und Offline-Kundenbindungsplattformen

Umfassende Multichannel-Kundeninteraktionsstrategie.

Engagement-Plattform	Jährliches Interaktionsvolumen
Kundendienstanrufe	14.230 Interaktionen
Live-Chat-Interaktionen	8.742 Sitzungen
Physische Beratungszentren	6 Standorte bundesweit

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Kundensegmente

Werdende Eltern

Cryo-Cell International richtet sich mit Bankdienstleistungen für Nabelschnurblut und Nabelschnurgewebe an werdende Eltern.

Segmentmerkmale	Marktgröße
Jährliche Geburten in den USA	3.661.220 (CDC-Daten 2022)
Mögliche Marktdurchdringung	Ungefähr 4-5 % der Geburten

Familien mit genetischen Gesundheitsproblemen

Kunden, die eine biologische Konservierung für potenzielle zukünftige medizinische Behandlungen wünschen.

• Familien mit Erbkrankheiten in der Vorgeschichte
• Genetische Veranlagung für bestimmte Gesundheitszustände

Prävalenz genetischer Krankheiten	Prozentsatz
Familien mit genetischem Störungsrisiko	3-5 % der Gesamtbevölkerung

Medizinische Forschungseinrichtungen

Forschungsorientiertes Kundensegment, das an biologischen Konservierungstechnologien interessiert ist.

Art der Forschungseinrichtung	Anzahl potenzieller Kunden
Akademische Forschungszentren	1.200 bundesweit
Private Forschungslabore	750 bundesweit

Personen, die sich für regenerative Medizin interessieren

Kunden, die fortschrittliche biologische Konservierungstechnologien erforschen.

Marktsegment	Geschätzte Größe
Markt für regenerative Medizin	180,5 Milliarden US-Dollar (2026 prognostiziert)

Fachkräfte im Gesundheitswesen

Mediziner suchen nach fortschrittlichen biologischen Konservierungslösungen.

• Onkologen
• Genetische Spezialisten
• Experten für Reproduktionsmedizin

Professionelle Kategorie	Totale Profis
Onkologen in den USA	14,680
Genetische Spezialisten	4,300

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Cryo-Cell International Forschungs- und Entwicklungskosten in Höhe von 1.243.000 US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	$1,243,000	12.4%
2022	$1,156,000	11.8%

Laborbetriebskosten

Die jährlichen Laborbetriebskosten für Cryo-Cell International beliefen sich im Jahr 2023 auf etwa 3.750.000 US-Dollar.

• Wartung der Anlage: 625.000 $
• Wertverlust der Ausrüstung: 1.125.000 USD
• Nebenkosten: 425.000 $
• Personalgehälter für Laborpersonal: 1.575.000 US-Dollar

Wartung und Upgrades der Technologie

Die technologiebezogenen Ausgaben für 2023 beliefen sich auf insgesamt 987.000 US-Dollar.

Kategorie der Technologieausgaben	Betrag
Software-Upgrades	$325,000
Hardware-Austausch	$412,000
Verbesserungen der Cybersicherheit	$250,000

Marketing- und Vertriebsausgaben

Die Marketing- und Vertriebskosten für Cryo-Cell International beliefen sich im Jahr 2023 auf 2.100.000 US-Dollar.

• Digitales Marketing: 675.000 US-Dollar
• Messebeteiligung: 425.000 $
• Vergütung des Vertriebsteams: 1.000.000 US-Dollar

Einhaltung gesetzlicher Vorschriften und Zertifizierung

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 875.000 US-Dollar.

Compliance-Kategorie	Betrag
FDA-Zertifizierung	$350,000
Kosten für externe Prüfungen	$275,000
Rechtsberatung	$250,000

Cryo-Cell International, Inc. (CCEL) – Geschäftsmodell: Einnahmequellen

Gebühren für die erste Entnahme von Nabelschnurblut und Gewebe

Cryo-Cell International erhebt eine anfängliche Inkassogebühr für Nabelschnurblut- und Gewebebankdienstleistungen. Ab 2023 liegt die Standardinkassogebühr je nach ausgewähltem Servicepaket zwischen 1.275 und 2.300 US-Dollar.

Servicepaket	Inkassogebühr
Nur Nabelschnurblut	$1,275
Nabelschnurblut und Gewebe	$2,300

Jährliche Aufbewahrungsgebühren für die Lagerung

Das Unternehmen generiert wiederkehrende Einnahmen durch jährliche Gebühren für die Aufbewahrung von Lagerbeständen. Die jährliche Lagergebühr beträgt etwa 175 US-Dollar pro Probe.

Zusätzliche Gentestdienste

Cryo-Cell bietet ergänzende Gentestdienste mit den folgenden Einnahmequellen an:

• Bewertung des genetischen Gesundheitsrisikos: 399 $
• Carrier-Screening: 249 $
• Personalisierte genetische Beratung: 250 $ pro Sitzung

Medizinische Forschungspartnerschaften

Im Jahr 2022 meldete Cryo-Cell einen Umsatz von rund 1,2 Millionen US-Dollar aus medizinischen Forschungskooperationen und Partnerschaften mit akademischen und pharmazeutischen Einrichtungen.

Einnahmen aus Beratungs- und Bildungsprogrammen

Programmtyp	Umsatz pro Programm
Professionelle medizinische Beratung	350 $ pro Sitzung
Bildungs-Webinar-Reihe	75–150 $ pro Teilnehmer

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Value Propositions

You're looking at the value Cryo-Cell International, Inc. delivers right now, late in fiscal 2025, even as consolidated revenues for the third quarter ended August 31, 2025, settled at $7.83 million, with net income at $749,000.

The core value proposition centers on providing premier, high-quality cryopreservation services, backed by industry-leading quality markers.

Premier, high-quality cord blood/tissue cryopreservation.

Cryo-Cell International, Inc. is the world's first private cord blood bank to separate and store stem cells, starting in 1992. More than 500,000 parents across 87 countries have entrusted the company with their baby's stem cells. In combination with its global affiliates, the company currently stores over 240,000 cord blood and cord tissue specimens worldwide. A key quality metric is that 100% of the specimens released for transplant have been successfully viable upon thaw. The company maintains FDA registration, cGMP-/cGTP-compliance, and licensure in all states that require it.

Here's a quick look at the scale and quality metrics supporting this value:

Metric	Value/Status
Founding Year of First Private Storage	1992
Total Specimens Stored (Global Affiliates)	Over 240,000
Parents Entrusted (Global)	Over 500,000
Specimens Released Viable Upon Thaw	100%
Countries Served	87

Access to advanced processing via exclusive PrepaCyte-CB technology.

Cryo-Cell International, Inc. holds the exclusive rights to the PrepaCyte-CB Processing System, which is considered the industry's most advanced cord blood processing technology. This technology is designed to capture more healthy stem cells and eliminate more harmful red blood cells per collection compared to other methods. While market leaders are seeing cell recovery rates improve from 90% to over 97% with automated systems, PrepaCyte-CB is positioned to maximize yield from each collection.

Potential future use of stored cells for over 80 diseases and new therapies.

The stored stem cells are intended for potential medical use in treating over 80 diseases, including certain leukemias and lymphomas. Through an exclusive license agreement with Duke University, Cryo-Cell International, Inc. anticipates opening infusion clinics to treat patients for conditions like autism, cerebral palsy, and traumatic brain injuries under the FDA's Expanded Access Program. The agreement also covers other clinical indications under study, such as adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

The potential therapeutic applications include:

• Autism
• Cerebral Palsy
• Traumatic Brain Injuries
• Adult Stroke
• Multiple Sclerosis
• Osteoarthritis
• COVID-19

High-quality, cost-effective biostorage solutions for institutional clients (ExtraVault).

In March 2022, Cryo-Cell International, Inc. launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. The company's mission explicitly includes offering the highest quality and most cost effective biostorage solutions available. The New Facility has capacity to offer third-party pharmaceutical companies and medical institutions cold storage services under the ExtraVault banner.

First U.S. private cord blood bank with FACT accreditation.

Cryo-Cell International, Inc. was the first private cord blood bank in the U.S. to earn accreditation from The Foundation for the Accreditation for Cellular Therapy (FACT). This accreditation confirms compliance with the NETCORD-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release. To give you context, the 10 top cancer centers in the U.S. are all FACT-accredited. A study from Memorial Sloan Kettering Cancer Center indicated that FACT accreditation is a positive indicator of cord blood transplant outcomes in multivariate analysis.

Finance: draft the Q4 2025 cash flow projection by next Tuesday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Relationships

You're looking at how Cryo-Cell International, Inc. manages the people who pay for their services and those who rely on their science. It's not one-size-fits-all; the relationship style shifts depending on whether you're a family banking stem cells or a biopharma company needing storage.

Long-term, high-touch relationship for private banking clients

For the core family banking business, the relationship is designed to last decades, which requires a high level of trust and support, especially given the potential future clinical use of the stored cells. This segment represents a significant base of committed customers.

Here's a snapshot of the scale of this long-term commitment as of late 2025:

Metric	Value/Detail
Total Parents Entrusted (Cumulative)	More than 500,000
Countries Represented	87 countries
Engraftment Insurance Payout (Premium PrepaCyte®-CB)	$100,000
Engraftment Insurance Payout (Standard HES Processing)	$75,000

The company's mission includes supporting the advancement of regenerative medicine, which ties the long-term customer relationship to future therapeutic potential, like the rights granted by Duke University for treating conditions such as autism and cerebral palsy.

Dedicated customer service for specimen retrieval and clinical use

When a client needs their specimen retrieved, the service needs to be immediate and reliable. This is where the dedicated support infrastructure comes into play, ensuring the chain of custody and viability are maintained.

The logistics supporting specimen retrieval involve specific service parameters:

• Courier service availability: 24 hours a day, 7 days a week.
• Shipping cost for Continental U.S. customers: Included in first-year fees.
• Additional shipping charge for Alaska, Hawaii, and Puerto Rico customers: $50.

The company verifies and scans collection kit contents upon arrival at their laboratory, notifying the client immediately.

Transactional and service-based for ExtraVault biopharma clients

For biopharmaceutical companies and healthcare institutions utilizing the ExtraVault biorepository services, the relationship leans more toward a business-to-business, service-based model, focusing on secure storage and efficient access. Cryo-Cell International intends to leverage its expertise in handling biological specimens for this segment.

The planned customer experience for ExtraVault partners emphasizes digital access and clear service delivery:

• Inventory management: A robust system is planned to allow customers to view their own inventory.
• Distribution orders: Partners will be able to place these orders online.
• Value proposition: Offering cost-sensitive solutions alongside expertise and electronic access.

Direct communication with investors via Investor Relations

Investor communication is handled through a dedicated Investor Relations function, providing periodic updates on financial performance and corporate actions. The website maintains specific sections for investors.

Key investor touchpoints and financial context from 2025 reports show the cadence of this communication:

Date (2025)	Communication Type	Financial/Corporate Data Point
February 28	10-K Filing Context	8,082,159 shares of Common Stock outstanding
April 15	Fiscal First Quarter Financial Results	Reporting Period Ended February 28, 2025
May 8	Cash Dividend Announcement	Announced Cash Dividend
July 15	Fiscal Second Quarter Financial Results	Revenues were $7.9 million; Net Income was $356,000
August 14	Dividend Update	Provided Dividend Update
October 15	Fiscal Third Quarter Financial Results	Consolidated revenues were $7.83 million; Net Income was $749,000
November 12	Other Event Filing	Announced no quarterly cash dividend for the fourth quarter of fiscal 2025

The company's stock trades on NYSE American LLC under the symbol CCEL.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Channels

You're looking at how Cryo-Cell International, Inc. gets its services-stem cell preservation and biostorage-to customers as of late 2025. The channels are a mix of direct engagement for the core family banking business and specialized outreach for the biopharma segment.

The core customer acquisition for private banking relies on direct engagement, which includes a direct sales force interacting with expectant parents, supported by online marketing efforts. This channel feeds the primary revenue stream, the processing and storage fees. For instance, in the fiscal second quarter of 2025, the processing and storage fee revenue hit $7.87 million out of total revenues of $7.9 million for that period. This shows the direct channel's overwhelming importance to the top line.

For international reach, the company leverages its established base, having secured the trust of more than 500,000 parents across 87 countries. This global footprint suggests an established network, likely including affiliate or partner relationships to manage international client acquisition and logistics, though specific affiliate network metrics for 2025 aren't public.

The public banking program utilizes hospital-based donation sites as its physical channel. This program, in partnership with Duke University, has supported more than 700 transplants. A key site mentioned is Cedars-Sinai Hospital in Los Angeles. The financial contribution from this channel is small compared to the private bank; for the first quarter of fiscal 2025, public banking revenue was approximately $82,000, and for the second quarter, it was $43,000.

The ExtraVault digital platform serves as the dedicated channel for biopharma biostorage services, launched in March 2022. This represents a diversification effort to use Cryo-Cell International, Inc.'s storage expertise for business-to-business clients. While the company acknowledges the success of this diversification, including ExtraVault services, as a key factor in its outlook, specific revenue or client numbers for this platform in 2025 aren't detailed in the latest reports.

Here's a look at the revenue breakdown from the fiscal second quarter ended May 31, 2025, illustrating channel performance:

Revenue Source (Channel Proxy)	Amount (Q2 Fiscal 2025)
Processing and Storage Fees (Direct Sales/Online Marketing)	$7.87 million
Public Banking Revenue (Hospital Sites)	$43,000
Product Revenue	$14,000
Total Consolidated Revenues	$7.9 million

You can see the reliance on the core service delivery. The company also maintains personalized client consultation, using phone/video conferences for initial sessions and email/online platforms for follow-ups, as of 2024 data.

• Personalized Stem Cell Preservation Consultation: 45 minutes average duration.
• Follow-up Consultation: 30 minutes average duration.
• Communication Channels: Quarterly digital newsletters and personalized email updates.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Segments

You're looking at the core groups Cryo-Cell International, Inc. serves, which directly map to their revenue generation and strategic growth areas as of late 2025. It's a mix of direct-to-consumer services and B2B/institutional support.

Expectant parents seeking private cord blood/tissue banking.

This is the bedrock of Cryo-Cell International, Inc.'s business. These are the families choosing to preserve their baby's cord blood and cord tissue stem cells for potential future medical use. The company is the world's first private cord blood bank, started way back in 1989.

The scale of this segment is significant:

• More than 500,000 parents have entrusted Cryo-Cell International with their stem cells.
• These parents hail from 87 countries.
• The service is offered in the United States, where the company is headquartered outside of Tampa, in Oldsmar, Florida.

Financially, this segment drives almost all the top-line revenue. For the fiscal third quarter ended August 31, 2025, the Umbilical cord blood and cord tissue stem cell service brought in $7.82 million, which was 99.94% of the total consolidated revenue for that quarter. That's a massive concentration of business in this one area. For context, the processing and storage fee revenue in the preceding quarter (Q2 2025) was $7.87 million.

Biopharmaceutical companies needing specialized biostorage.

Cryo-Cell International, Inc. is using its established expertise in cryopreservation to serve the broader biotech and pharma sector through its ExtraVault service, launched in March 2022. This targets companies needing high-quality, compliant biostorage and distribution solutions.

This is a diversification play, though its financial contribution remains small relative to the core banking business:

• ExtraVault offers expertise in biostorage and distribution.
• Product revenue for the second quarter of fiscal 2025 was only $14,000.
• For the full fiscal year 2024, product revenue totaled $68,000.

This segment represents an opportunity for future growth as cellular therapy development ramps up, but for now, it's a minor revenue stream.

Healthcare institutions utilizing the public cord blood bank.

The public banking program is run in partnership with Duke University. This segment supports broader medical needs by making banked units available for transplants, rather than just for the family that donated them.

The impact here is measured in lives saved through transplantation:

• The public bank has provided cord blood for more than 700 transplants.
• Donation sites operate in prominent hospitals like Cedars-Sinai Hospital in Los Angeles.
• Public banking revenue in Q2 2025 was $43,000.
• Public banking revenue for fiscal 2024 was $367,000.

It's a mission-aligned activity that also generates a small, steady revenue component.

Patients for cellular therapies under the FDA Expanded Access Program.

This is a forward-looking segment tied to Cryo-Cell International, Inc.'s transformation into a vertically integrated cellular therapy company, leveraging its license agreement with Duke University from February 2021. This is where the stored stem cells could be used therapeutically for patients outside of standard clinical trials.

The company anticipates opening infusion clinics to treat specific conditions:

• Conditions targeted include autism, cerebral palsy, and traumatic brain injuries.
• Other indications being studied under the license include adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

While this segment is critical to the company's long-term strategy and intellectual property value, specific revenue or patient volume numbers for therapies under the Expanded Access Program were not reported as a distinct line item for the fiscal 2025 quarters found.

Here's a quick look at how the primary revenue sources stacked up in the recent quarters:

Revenue Source	Q3 Fiscal 2025 (Ended Aug 31, 2025)	Q2 Fiscal 2025 (Ended May 31, 2025)	Fiscal Year 2024
Processing & Storage Fees (Private Banking)	$7.82 Million (99.94%)	$7.87 Million	$31.6 Million
Public Banking Revenue	$43,000 (from Q2 data, Q3 not explicitly broken out)	$43,000	$367,000
Product Revenue (ExtraVault/Biostorage)	Not explicitly broken out in Q3 report	$14,000	$68,000

Overall consolidated revenues for Q3 2025 were $7.83 million, down 3% from Q3 2024's $8.07 million. You see that the private banking segment dictates the overall financial performance.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cryo-Cell International, Inc. (CCEL) operation as of late 2025. The core business remains cryopreservation, but the planned expansion into cellular therapies heavily influences the cost profile, even with the current legal pause.

Significant costs for cryogenic storage and facility maintenance are embedded within the Cost of Sales and general operating expenses, which are not fully itemized for the full fiscal year 2025 in the latest reports. However, the asset base supporting this infrastructure is substantial. Property and Equipment-net stood at $21,391,845 as of May 31, 2025. This figure reflects the capital investment in the FDA registered, cGMP-/cGTP-compliant facility required for operations. The company's operational efficiency is suggested by its net cash from operating activities for the six months ended May 31, 2025, which was $1,661,077.

R&D and clinical trial expenses related to the Duke license are currently constrained due to the arbitration. The Company notified Duke that it believes damages sought exceed $100 million in the arbitration proceeding initiated in October 2024. Because of this dispute, Cryo-Cell International, Inc. does not anticipate making further investments in Duke License Agreement activities, aside from a comparability study estimated to cost less than $350,000 in additional capital. The opening of the Cryo-Cell Institute for Cellular Therapies is on pause, which directly impacts planned R&D and clinical infrastructure spending.

Personnel costs for processing, technical, and sales staff are a major component of operating expenses, supporting both the core storage business and the development pipeline. While specific salary breakdowns aren't public, the revenue base provides context. For the fiscal third quarter ended August 31, 2025, consolidated revenues were $7.83 million. The net income for that same quarter was $749,000, or $0.09 per basic and diluted share. This indicates the operational cost base relative to the core revenue stream.

Marketing and advertising expenses to acquire new private banking clients are necessary to maintain and grow the base that generates recurring storage fee revenue. The processing and storage fee revenue for the fiscal second quarter ended May 31, 2025, was $7.87 million. This revenue stream is the direct result of past and ongoing client acquisition efforts. The company has served over 500,000 parents from 87 countries.

Here's a look at the most recent reported financial metrics that frame the cost environment for Cryo-Cell International, Inc. as of late 2025:

Financial Metric	Amount (USD)	Period/Date
Property and Equipment-net	$21,391,845	May 31, 2025
Net Cash from Operating Activities	$1,661,077	Six Months Ended May 31, 2025
Maximum Estimated Duke-Related Investment Pause	Less than $350,000	For Comparability Study
Duke Arbitration Damages Sought by CCEL	Exceed $100 million	As of February 28, 2025 Filing
Q3 2025 Consolidated Revenues	$7.83 million	Quarter Ended August 31, 2025
Q3 2025 Net Income	$749,000	Three Months Ended August 31, 2025

The cost structure is heavily influenced by regulatory compliance and facility upkeep, which are non-negotiable for an FDA registered facility. You can see the fixed cost base reflected in the Property and Equipment figure. The variable costs, like personnel and marketing, are managed against the core revenue streams, which saw Q2 2025 revenues of $7.9 million and Q3 2025 revenues of $7.83 million.

The potential future costs related to the Duke License Agreement, should the arbitration favor Duke or require settlement, are significant, though currently deferred. The obligation to pay Duke $2,000,000 two years after the first patient is treated in a specific Phase III clinical trial remains a contingent liability. Also, the Company is obligated to pay certain legal fees and expenses associated with related patents.

Key cost drivers and related metrics include:

• Cryogenic Storage Capacity: Supporting over 500,000 stored units.
• Facility Compliance: Facility is FDA registered, cGMP-/cGTP-compliant.
• Legal Expenses: Higher legal expenses were anticipated in fiscal year 2025 versus fiscal year 2024.
• Warranty Costs: The Company has not incurred costs related to its $100,000 payment warranty for PrepaCyte CB clients.

Finance: draft 13-week cash view by Friday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Revenue Streams

You want the hard numbers on how Cryo-Cell International, Inc. is bringing in cash right now, based on the latest filings. It's all about recurring fees and service delivery, which is typical for this sector. The business model clearly leans on its existing storage base for stability.

Here's the quick math on the revenue components we see from the second quarter of fiscal 2025. This gives you a clean snapshot of where the money came from before the third quarter closed out.

The core revenue streams for Cryo-Cell International, Inc. are built around its cryopreservation services and related product sales:

• Processing and storage fee revenue, which hit $7.87 million in Q2 2025.
• Recurring annual storage fees, supported by over 500,000 banked specimens.
• Public banking revenue, coming in at $43,000 for Q2 2025.
• Product revenue from PrepaCyte-CB sales, which was $14,000 in Q2 2025.

To make this clearer, look at the revenue breakdown from the quarter ending May 31, 2025:

Revenue Component	Q2 2025 Amount
Processing and Storage Fee Revenue	$7.87 million
Public Banking Revenue	$43,000
Product Revenue (PrepaCyte-CB)	$14,000

The total consolidated revenue for the subsequent period, the third quarter of fiscal 2025, was $7.83 million. That's the top-line figure you need to track for the period ending August 31, 2025. It's defintely important to watch the trend between Q2 and Q3.

Finance: draft 13-week cash view by Friday.